Adrian S Ray

List of Publications by Year
in descending order

102 papers	11,018 citations	44069 48 h-index	31849 101 g-index
105 all docs	105 docs citations	105 times ranked	12634 citing authors

#	Article	IF	Citations
1	HCV RdRp, sofosbuvir and beyond. The Enzymes, 2021, 49, 63-82.	1.7	5
2	Species differences in liver accumulation and metabolism of nucleotide prodrug sofosbuvir. Drug Metabolism and Pharmacokinetics, 2020, 35, 334-340.	2.2	11
3	Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. MBio, 2018, 9, .	4.1	1,142
4	Sofosbuvir and Ribavirin Liver Pharmacokinetics in Patients Infected with Hepatitis C Virus. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	29
5	Transporter Expression in Noncancerous and Cancerous Liver Tissue from Donors with Hepatocellular Carcinoma and Chronic Hepatitis C Infection Quantified by LC-MS/MS Proteomics. Drug Metabolism and Disposition, 2018, 46, 189-196.	3.3	43
6	Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology, 2018, 16, 1983-1991.e3.	4.4	153
7	GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology, 2018, 155, 1463-1473.e6.	1.3	238
8	Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance. Clinical Pharmacology and Therapeutics, 2018, 104, 890-899.	4.7	185
9	Nucleotide Prodrug Containing a Nonproteinogenic Amino Acid To Improve Oral Delivery of a Hepatitis C Virus Treatment. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	6
10	Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses. Journal of Medicinal Chemistry, 2017, 60, 1648-1661.	6.4	547
11	Tenofovir alafenamide (TAF) does not deplete mitochondrial DNA in human T-cell lines at intracellular concentrations exceeding clinically relevant drug exposures. Antiviral Research, 2017, 140, 116-120.	4.1	18
12	Discovery of a 2â€²-fluoro-2â€²- C -methyl C -nucleotide HCV polymerase inhibitor and a phosphoramidate prodrug with favorable properties. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 1840-1847.	2.2	7
13	GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses. Scientific Reports, 2017, 7, 43395.	3.3	373
14	Interaction of 2,4-Diaminopyrimidineâ€“Containing Drugs Including Fedratinib and Trimethoprim with Thiamine Transporters. Drug Metabolism and Disposition, 2017, 45, 76-85.	3.3	30
15	Beyond drug-drug interactions: effects of transporter inhibition on endobiotics, nutrients and toxins. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 1075-1087.	3.3	20
16	Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Science Translational Medicine, 2017, 9, .	12.4	1,279
17	Role of Mitochondrial Toxicity in BMS-986094-Induced Toxicity. Toxicological Sciences, 2017, 155, 2-2.	3.1	7
18	Viability of primary osteoblasts after treatment with tenofovir alafenamide: Lack of cytotoxicity at clinically relevant drug concentrations. PLoS ONE, 2017, 12, e0169948.	2.5	7

#	Article	IF	Citations
19	Transporter Expression in Liver Tissue from Subjects with Alcoholic or Hepatitis C Cirrhosis Quantified by Targeted Quantitative Proteomics. Drug Metabolism and Disposition, 2016, 44, 1752-1758.	3.3	100
20	Renal Transporterâ€Mediated Drugâ€Drug Interactions: Are They Clinically Relevant?. Journal of Clinical Pharmacology, 2016, 56, S73-81.	2.0	28
21	Chemoprophylaxis With Oral Emtricitabine and Tenofovir Alafenamide Combination Protects Macaques From Rectal Simian/Human Immunodeficiency Virus Infection. Journal of Infectious Diseases, 2016, 214, 1058-1062.	4.0	28
22	Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature, 2016, 531, 381-385.	27.8	1,245
23	Involvement of Drug Transporters in Organ Toxicity: The Fundamental Basis of Drug Discovery and Development. Chemical Research in Toxicology, 2016, 29, 545-563.	3.3	18
24	Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus. Antiviral Research, 2016, 125, 63-70.	4.1	302
25	Role of Mitochondrial RNA Polymerase in the Toxicity of Nucleotide Inhibitors of Hepatitis C Virus. Antimicrobial Agents and Chemotherapy, 2016, 60, 806-817.	3.2	68
26	Implications of Efficient Hepatic Delivery by Tenofovir Alafenamide (GS-7340) for Hepatitis B Virus Therapy. Antimicrobial Agents and Chemotherapy, 2015, 59, 3563-3569.	3.2	133
27	Structural basis for RNA replication by the hepatitis C virus polymerase. Science, 2015, 347, 771-775.	12.6	294
28	Synthesis and characterization of 1â€²-C-cyano-2â€²-fluoro-2â€²-C-methyl pyrimidine nucleosides as HCV polymerase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 1040-1043.	2.2	3
29	A pharmacogenetic candidate gene study of tenofovir-associated Fanconi syndrome. Pharmacogenetics and Genomics, 2015, 25, 82-92.	1.5	27
30	Synthesis of 1â€²-C-Cyano Pyrimidine Nucleosides and Characterization as HCV Polymerase Inhibitors. Nucleosides, Nucleotides and Nucleic Acids, 2015, 34, 763-785.	1.1	6
31	Metformin Is a Substrate and Inhibitor of the Human Thiamine Transporter, THTR-2 (SLC19A3). Molecular Pharmaceutics, 2015, 12, 4301-4310.	4.6	79
32	Evaluation of the Endothelin Receptor Antagonists Ambrisentan, Bosentan, Macitentan, and Sitaxsentan as Hepatobiliary Transporter Inhibitors and Substrates in Sandwich-Cultured Human Hepatocytes. PLoS ONE, 2014, 9, e87548.	2.5	63
33	Pharmacokinetics of cobicistat boostedâ€elvitegravir administered in combination with rosuvastatin. Journal of Clinical Pharmacology, 2014, 54, 649-656.	2.0	32
34	GS-9219/VDC-1101 - a prodrug of the acyclic nucleotide PMEG has antitumor activity inspontaneous canine multiple myeloma. BMC Veterinary Research, 2014, 10, 30.	1.9	19
35	Inhibition of Hepatitis C Virus Replication by GS-6620, a Potent C -Nucleoside Monophosphate Prodrug. Antimicrobial Agents and Chemotherapy, 2014, 58, 1930-1942.	3.2	38
36	Metabolism and Pharmacokinetics of the Anti-Hepatitis C Virus Nucleotide Prodrug GS-6620. Antimicrobial Agents and Chemotherapy, 2014, 58, 1943-1951.	3.2	40

#	Article	IF	Citations
37	Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat. Kidney International, 2014, 86, 350-357.	5.2	198
38	Preparation and biological evaluation of 1â€²-cyano-2â€²-C-methyl pyrimidine nucleosides as HCV NS5B polymerase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 3092-3095.	2.2	11
39	Discovery of the First C-Nucleoside HCV Polymerase Inhibitor (GS-6620) with Demonstrated Antiviral Response in HCV Infected Patients. Journal of Medicinal Chemistry, 2014, 57, 1812-1825.	6.4	108
40	Bifunctional inhibition of HIV-1 reverse transcriptase: A first step in designing a bifunctional triphosphate. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 1511-1518.	2.2	7
41	Evaluation of 2â€²-Î±-fluorine modified nucleoside phosphonates as potential inhibitors of HCV polymerase. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 3354-3357.	2.2	9
42	Mechanism for Effective Lymphoid Cell and Tissue Loading Following Oral Administration of Nucleotide Prodrug GS-7340. Molecular Pharmaceutics, 2013, 10, 459-466.	4.6	93
43	Evaluation of the Effect of Cobicistat on the In Vitro Renal Transport and Cytotoxicity Potential of Tenofovir. Antimicrobial Agents and Chemotherapy, 2013, 57, 4982-4989.	3.2	41
44	Sensitivity of Mitochondrial Transcription and Resistance of RNA Polymerase II Dependent Nuclear Transcription to Antiviral Ribonucleosides. PLoS Pathogens, 2012, 8, e1003030.	4.7	119
45	Compared to Subcutaneous Tenofovir, Oral Tenofovir Disoproxyl Fumarate Administration Preferentially Concentrates the Drug into Gut-Associated Lymphoid Cells in Simian Immunodeficiency Virus-Infected Macaques. Antimicrobial Agents and Chemotherapy, 2012, 56, 4980-4984.	3.2	10
46	Renal drugâ€“drug interactions: what we have learned and where we are going. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 433-448.	3.3	54
47	Cobicistat Boosts the Intestinal Absorption of Transport Substrates, Including HIV Protease Inhibitors and GS-7340, In Vitro. Antimicrobial Agents and Chemotherapy, 2012, 56, 5409-5413.	3.2	126
48	Metabolic Activation of the Anti-Hepatitis C Virus Nucleotide Prodrug PSI-352938. Antimicrobial Agents and Chemotherapy, 2012, 56, 3767-3775.	3.2	24
49	Synthesis and antiviral activity of a series of 1â€²-substituted 4-aza-7,9-dideazaadenosine C-nucleosides. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 2705-2707.	2.2	173
50	Synthesis and characterization of 2â€²-C-Me branched C-nucleosides as HCV polymerase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 4127-4132.	2.2	37
51	Intracellular Nucleotide Levels during Coadministration of Tenofovir Disoproxil Fumarate and Didanosine in HIV-1-Infected Patients. Antimicrobial Agents and Chemotherapy, 2011, 55, 1549-1555.	3.2	15
52	Synthesis and Significant Cytostatic Activity of 7-Hetaryl-7-deazaadenosines. Journal of Medicinal Chemistry, 2011, 54, 5498-5507.	6.4	101
53	Application of kinase bypass strategies to nucleoside antivirals. Antiviral Research, 2011, 92, 277-291.	4.1	39
54	Natural Substrate Concentrations Can Modulate the Prophylactic Efficacy of Nucleotide HIV Reverse Transcriptase Inhibitors. Journal of Virology, 2011, 85, 6610-6617.	3.4	69

#	Article	IF	Citations
55	Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine. Antiviral Research, 2010, 85, 39-58.	4.1	314
56	Discovery of GS-9131: Design, synthesis and optimization of amidate prodrugs of the novel nucleoside phosphonate HIV reverse transcriptase (RT) inhibitor GS-9148. Bioorganic and Medicinal Chemistry, 2010, 18, 3606-3617.	3.0	57
57	6-(Het)aryl-7-Deazapurine Ribonucleosides as Novel Potent Cytostatic Agents. Journal of Medicinal Chemistry, 2010, 53, 460-470.	6.4	73
58	Visualizing the Molecular Interactions of a Nucleotide Analog, GS-9148, with HIV-1 Reverse Transcriptaseâ€“DNA Complex. Journal of Molecular Biology, 2010, 397, 967-978.	4.2	48
59	HCV NS5B polymerase inhibitors. Current Opinion in Drug Discovery & Development, 2010, 13, 441-65.	1.9	15
60	Novel Nucleotide Human Immunodeficiency Virus Reverse Transcriptase Inhibitor GS-9148 with a Low Nephrotoxic Potential: Characterization of Renal Transport and Accumulation. Antimicrobial Agents and Chemotherapy, 2009, 53, 150-156.	3.2	52
61	GS-9191 Is a Novel Topical Prodrug of the Nucleotide Analog 9-(2-Phosphonylmethoxyethyl)Guanine with Antiproliferative Activity and Possible Utility in the Treatment of Human Papillomavirus Lesions. Antimicrobial Agents and Chemotherapy, 2009, 53, 2777-2784.	3.2	37
62	Assessment of GS-9219 in a Pet Dog Model of Non-Hodgkin's Lymphoma. Clinical Cancer Research, 2009, 15, 3503-3510.	7.0	58
63	Targeting DNA Repair in Chronic Lymphocytic Leukemia Cells with a Novel Acyclic Nucleotide Analogue, GS-9219. Clinical Cancer Research, 2009, 15, 3760-3769.	7.0	10
64	Design, synthesis, and anti-HIV activity of 4â€²-modified carbocyclic nucleoside phosphonate reverse transcriptase inhibitors. Bioorganic and Medicinal Chemistry, 2009, 17, 1739-1746.	3.0	58
65	Nucleotide Analogue Prodrug Tenofovir Disoproxil Enhances Lymphoid Cell Loading following Oral Administration in Monkeys. Molecular Pharmaceutics, 2009, 6, 1145-1151.	4.6	52
66	Synthesis and anti-HIV activity of GS-9148 (2â€²-Fd4AP), a novel nucleoside phosphonate HIV reverse transcriptase inhibitor. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 1120-1123.	2.2	58
67	Synthesis and anti-HIV activity of 2â€²-fluorine modified nucleoside phosphonates: Analogs of GS-9148. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 1116-1119.	2.2	26
68	Design and Profiling of GS-9148, a Novel Nucleotide Analog Active against Nucleoside-Resistant Variants of Human Immunodeficiency Virus Type 1, and Its Orally Bioavailable Phosphonoamidate Prodrug, GS-9131. Antimicrobial Agents and Chemotherapy, 2008, 52, 655-665.	3.2	93
69	Chronic Administration of Tenofovir to Rhesus Macaques from Infancy through Adulthood and Pregnancy: Summary of Pharmacokinetics and Biological and Virological Effects. Antimicrobial Agents and Chemotherapy, 2008, 52, 3144-3160.	3.2	114
70	Intracellular Metabolism of the Nucleotide Prodrug GS-9131, a Potent Anti-Human Immunodeficiency Virus Agent. Antimicrobial Agents and Chemotherapy, 2008, 52, 648-654.	3.2	58
71	GS-9219â€”A Novel Acyclic Nucleotide Analogue with Potent Antineoplastic Activity in Dogs with Spontaneous Nonâ€“Hodgkin's Lymphoma. Clinical Cancer Research, 2008, 14, 2824-2832.	7.0	74
72	Effect of nucleoside and nucleotide reverse transcriptase inhibitors of HIV on endogenous nucleotide pools. Antiviral Therapy, 2008, 13, 789-97.	1.0	11

#	Article	IF	Citations
73	Effect of Nucleoside and Nucleotide Reverse Transcriptase Inhibitors of HIV on Endogenous Nucleotide Pools. Antiviral Therapy, 2008, 13, 789-797.	1.0	17
74	Unlikely Association of Multidrugâ€Resistance Protein 2 Singleâ€Nucleotide Polymorphisms with Tenofovirâ€Induced Renal Adverse Events. Journal of Infectious Diseases, 2007, 195, 1389-1390.	4.0	9
75	Interaction of 2â€²-deoxyguanosine Triphosphate Analogue Inhibitors of HIV Reverse Transcriptase with Human Mitochondrial DNA Polymerase Î³. Antiviral Chemistry and Chemotherapy, 2007, 18, 25-33.	0.6	4
76	Effects of Human Immunodeficiency Virus Protease Inhibitors on the Intestinal Absorption of Tenofovir Disoproxil Fumarate In Vitro. Antimicrobial Agents and Chemotherapy, 2007, 51, 3498-3504.	3.2	118
77	Synthesis, anti-HIV activity, and resistance profiles of ribose modified nucleoside phosphonates. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 6785-6789.	2.2	31
78	Simultaneous quantitation of the nucleotide analog adefovir, its phosphorylated anabolites and 2â€²-deoxyadenosine triphosphate by ion-pairing LC/MS/MS. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 848, 335-343.	2.3	54
79	Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors. Antiviral Therapy, 2007, 12, 267-72.	1.0	33
80	Molecular Assessment of the Potential for Renal Drug Interactions between Tenofovir and HIV Protease Inhibitors. Antiviral Therapy, 2007, 12, 267-272.	1.0	76
81	Intracellular Metabolism and In Vitro Activity of Tenofovir against Hepatitis B Virus. Antimicrobial Agents and Chemotherapy, 2006, 50, 2471-2477.	3.2	221
82	Mechanism of Active Renal Tubular Efflux of Tenofovir. Antimicrobial Agents and Chemotherapy, 2006, 50, 3297-3304.	3.2	298
83	In VitroEvaluation of the Anti-HIV Activity and Metabolic Interactions of Tenofovir and Emtricitabine. Antiviral Therapy, 2006, 11, 377-384.	1.0	60
84	The K65R Reverse Transcriptase Mutation in HIV-1 Reverses the Excision Phenotype of Zidovudine Resistance Mutations. Antiviral Therapy, 2006, 11, 155-163.	1.0	69
85	A combination of decreased NRTI incorporation and decreased excision determines the resistance profile of HIV-1 K65R RT. Aids, 2005, 19, 1751-1760.	2.2	70
86	Mechanism of Anti-Human Immunodeficiency Virus Activity of Î²- d -6-Cyclopropylamino-2â€²,3â€²-Didehydro-2â€²,3â€²-Dideoxyguanosine. Antimicrobial Agents and Chemotherapy, 2005, 49, 1994-2001.	3.2	5
87	Lack of a metabolic and antiviral drug interaction between tenofovir, abacavir and lamivudine. Antiviral Therapy, 2005, 10, 451-7.	1.0	9
88	Intracellular interactions between nucleos(t)ide inhibitors of HIV reverse transcriptase. AIDS Reviews, 2005, 7, 113-25.	1.0	31
89	Lack of a Metabolic and Antiviral Drug Interaction between Tenofovir, Abacavir and Lamivudine. Antiviral Therapy, 2005, 10, 451-457.	1.0	30
90	Investigating the effects of stereochemistry on incorporation and removal of 5-fluorocytidine analogs by mitochondrial DNA polymerase gamma: comparison of d- and l-D4FC-TP. Antiviral Research, 2004, 62, 57-64.	4.1	14

#	Article	IF	Citations
91	Effective metabolism and long intracellular half life of the anti-Hepatitis B agent adefovir in hepatic cells. Biochemical Pharmacology, 2004, 68, 1825-1831.	4.4	36
92	2 â€² ,3 â€² -Didehydro-2 â€² ,3 â€² -dideoxynucleosides are degraded to furfuryl alcohol under acidic conditions. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 2159-2162.	2.2	7
93	Role of Purine Nucleoside Phosphorylase in Interactions between 2â€²,3â€²-Dideoxyinosine and Allopurinol, Ganciclovir, or Tenofovir. Antimicrobial Agents and Chemotherapy, 2004, 48, 1089-1095.	3.2	132
94	Probing the Molecular Mechanisms of AZT Drug Resistance Mediated by HIV-1 Reverse Transcriptase Using a Transient Kinetic Analysisâ€. Biochemistry, 2003, 42, 8831-8841.	2.5	75
95	Probing the Mechanistic Consequences of 5-Fluorine Substitution on Cytidine Nucleotide Analogue Incorporation by HIV-1 Reverse Transcriptase. Antiviral Chemistry and Chemotherapy, 2003, 14, 115-125.	0.6	22
96	Mechanistic Studies to Understand the Progressive Development of Resistance in Human Immunodeficiency Virus Type 1 Reverse Transcriptase to Abacavir. Journal of Biological Chemistry, 2002, 277, 40479-40490.	3.4	56
97	Novel Use of a Guanosine Prodrug Approach To Convert 2',3'-Didehydro-2',3'-Dideoxyguanosine into a Viable Antiviral Agent. Antimicrobial Agents and Chemotherapy, 2002, 46, 887-891.	3.2	36
98	Insights into the Molecular Mechanism of Inhibition and Drug Resistance for HIV-1 RT with Carbovir Triphosphateâ€. Biochemistry, 2002, 41, 5150-5162.	2.5	42
99	Interactions of enantiomers of 2â€²,3â€²-didehydro-2â€²,3â€²-dideoxy-fluorocytidine with wild type and M184V mutant HIV-1 reverse transcriptase. Antiviral Research, 2002, 56, 189-205.	4.1	24
100	MECHANISTIC STUDIES TO UNDERSTAND THE INHIBITION OF WILD TYPE AND MUTANT HIV-1 REVERSE TRANSCRIPTASE BY CARBOVIR-TRIPHOSPHATE. Nucleosides, Nucleotides and Nucleic Acids, 2001, 20, 1247-1250.	1.1	11
101	Toxicity of Antiviral Nucleoside Analogs and the Human Mitochondrial DNA Polymerase. Journal of Biological Chemistry, 2001, 276, 40847-40857.	3.4	362
102	Metabolism of Antiviral Nucleosides and Nucleotides. , 0, , 301-315.		1